| Multiple Sclerosis, Relapsing-Remitting
Mavenclad vs Zeposia
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Mavenclad vs Zeposia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZeposia has a higher rate of injection site reactions vs Mavenclad based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zeposia but not Mavenclad, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mavenclad
Zeposia
At A Glance
Oral
2 yearly treatment courses
Nucleoside metabolic inhibitor
Oral
Once daily
S1P receptor modulator
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Ulcerative Colitis
Dosing
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Cumulative dose of 3.5 mg/kg administered orally, divided into 2 yearly treatment courses (1.75 mg/kg per course); each course consists of 2 cycles of 4 to 5 consecutive days of dosing; no more than 2 tablets (20 mg) per day; do not administer additional treatment during the 2 years following completion of 2 courses.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome, Ulcerative Colitis Initiate with 7-day titration (0.23 mg once daily days 1-4, 0.46 mg once daily days 5-7); maintenance dose 0.92 mg orally once daily starting day 8; patients with mild or moderate hepatic impairment (Child-Pugh class A or B) take 0.92 mg once every other day after titration.
Contraindications
- Current malignancy
- Pregnancy, or women or men of reproductive potential not using effective contraception during dosing and for 6 months after the last dose in each treatment course
- HIV infection
- Active chronic infections (e.g., hepatitis or tuberculosis)
- History of hypersensitivity to cladribine
- Breastfeeding on a treatment day and for 10 days after the last dose
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months
- Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
- Severe untreated sleep apnea
- Concurrent use of a monoamine oxidase (MAO) inhibitor
Adverse Reactions
Most common (>20%) Upper respiratory tract infection, headache, lymphopenia
Serious Malignancies, teratogenicity, lymphopenia, infections, hematologic toxicity, graft-versus-host disease with blood transfusion, liver injury, hypersensitivity, cardiac failure, seizures, myelodysplastic syndrome
Postmarketing Nocardiosis, varicella zoster, histoplasmosis, cryptococcosis, toxoplasmosis, liver injury
Most common (>=4%) Upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, hypertension (MS); liver test increased, upper respiratory infection, headache (UC)
Serious Infections, progressive multifocal leukoencephalopathy, bradyarrhythmia and AV conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, cutaneous malignancies, posterior reversible encephalopathy syndrome
Postmarketing Liver injury
Pharmacology
Cladribine is a nucleoside metabolic inhibitor that exerts cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes; this lymphocyte-depleting mechanism is thought to underlie its therapeutic effects in relapsing forms of multiple sclerosis.
Ozanimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in MS and ulcerative colitis is unknown but may involve reduced lymphocyte migration into the CNS and intestine.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mavenclad
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Zeposia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Mavenclad
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Zeposia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Mavenclad
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (1/3)
Zeposia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Zeposia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MavencladView full Mavenclad profile
ZeposiaView full Zeposia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.